|
Real-time
Oslo Bors
17:27:21 20/11/2026 HKT
|
5-day change | 1st Jan Change | ||
| 0.4020 NOK | -1.71% |
|
+0.50% | -90.65% |
| 11-13 | Induct AS Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026 | CI |
| 10-13 | Induct AS Expands Scope of Existing Severe Asthma Care Pathway | CI |
Projected Income Statement: Induct
Annual
Quarterly
Annual
Quarterly
| Fiscal Period: December | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| Net sales 1 | 16.58 | 13.8 | 16.9 | 26.1 |
| Change | - | -16.79% | 22.46% | 54.44% |
| EBITDA 1 | - | 3.6 | 4.5 | 11 |
| Change | - | - | 25% | 144.44% |
| EBIT 1 | - | -9.9 | -7.2 | -0.7 |
| Change | - | - | 27.27% | 90.28% |
| Interest Paid 1 | - | -0.6 | -0.5 | -0.9 |
| Earnings before Tax (EBT) 1 | - | -10.5 | -7.7 | -1.6 |
| Change | - | - | 26.67% | 79.22% |
| Net income 1 | -7.14 | -10.5 | -7.7 | -1.7 |
| Change | - | -47.06% | 26.67% | 77.92% |
| Announcement Date | 12/2/26 | - | - | - |
1NOK in Million
Estimates
Forecast Balance Sheet: Induct
| Fiscal Period: December | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| Net Debt 1 | - | -1.5 | 7.5 | 11.9 |
| Change | - | - | 600% | 58.67% |
| Announcement Date | 12/2/26 | - | - | - |
1NOK in Million
Estimates
Cash Flow Forecast: Induct
| Fiscal Period: December | 2026 | 2027 | 2028 |
|---|---|---|---|
| CAPEX 1 | 9 | 12 | 12 |
| Change | - | 33.33% | 0% |
| Free Cash Flow (FCF) 1 | -4 | -9 | -4 |
| Change | - | -125% | 55.56% |
| Announcement Date | - | - | - |
1NOK in Million
Estimates
Forecast Financial Ratios: Induct
| Fiscal Period: December | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
Profitability | ||||
| EBITDA Margin (%) | - | 26.09% | 26.63% | 42.15% |
| EBIT Margin (%) | - | -71.74% | -42.6% | -2.68% |
| EBT Margin (%) | - | -76.09% | -45.56% | -6.13% |
| Net margin (%) | -43.05% | -76.09% | -45.56% | -6.51% |
| FCF margin (%) | - | -28.99% | -53.25% | -15.33% |
| FCF / Net Income (%) | - | 38.1% | 116.88% | 235.29% |
Profitability | ||||
| ROA | - | - | - | - |
| ROE | - | -28% | -22% | -6% |
Financial Health | ||||
| Leverage (Debt/EBITDA) | - | - | 1.67x | 1.08x |
| Debt / Free cash flow | - | - | -0.83x | -2.98x |
Capital Intensity | ||||
| CAPEX / Current Assets (%) | - | 65.22% | 71.01% | 45.98% |
| CAPEX / EBITDA (%) | - | 250% | 266.67% | 109.09% |
| CAPEX / FCF (%) | - | -225% | -133.33% | -300% |
Items per share | ||||
| Cash flow per share 1 | - | - | - | - |
| Change | - | - | - | - |
| Dividend per Share 1 | - | - | - | - |
| Change | - | - | - | - |
| Book Value Per Share 1 | - | - | - | - |
| Change | - | - | - | - |
| EPS 1 | - | -0.26 | -0.15 | -0.03 |
| Change | - | - | 42.31% | 80% |
| Nbr of stocks (in thousands) | - | 50,309 | 50,309 | 50,309 |
| Announcement Date | - | - | - | - |
1NOK
Estimates
| 2026 * | 2027 * | |
|---|---|---|
| P/E | -1.57x | -2.73x |
| PBR | - | - |
| EV / Sales | 1.38x | 1.66x |
| Yield | - | - |
EPS & Dividend
Y-o-Y evolution of P/E
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.4090NOK
Average target price
1.100NOK
Spread / Average Target
+168.95%
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- INDCT Stock
- Financials Induct
Select your edition
All financial news and data tailored to specific country editions
















